跳至主要内容
临床试验/NCT02546310
NCT02546310已完成1 期

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase 1, Exploratory Study Investigating the Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects

Heptares Therapeutics Limited1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2015年10月最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
54
试验地点
1
主要终点
Blood oxygen level dependent (BOLD) signal in functional Magnetic Resonance Imaging (fMRI) of the brain areas associated with cognitive tasks

研究概览

简要总结

To determine if treatment with HTL0009936 will lead to changes in neural activity, measured using the fMRI BOLD signal and ASL, in brain areas that are associated with spatial and working memory, learning and executive functioning.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
65 Years 至 80 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy on the basis of medical history, physical examination, vital signs, 12-lead ECG, haematology, blood chemistry, urinalysis and a pre-study psychological assessment.
  • Mini Mental State Examination (MMSE) Score of ≥
  • Intermediate or extensive metaboliser as determined by CYP2D6 genotype.
  • Fluent English speaker.
  • Right-handed.
  • Not a regular smoker

排除标准

  • Recreational drug use within 3 months prior to Screening Visit.
  • Positive alcohol breath test.
  • Positive urine drug screen.
  • Consumption of large amounts of caffeinated drinks.
  • Consumption of any food or any drinks containing cranberry, pomegranate, star fruit, grapefruit, pomelos, exotic citrus fruits or Seville oranges.
  • Ultra-rapid or poor metabolizer as determined by CYP2D6 genotype.
  • By self-report, taking two or more daytime naps per week which in the opinion of the investigator is likely to interfere with the ability of the subject to complete the study procedures.
  • History of, or presents (in the opinion of the Investigator) with, significant neurological or psychiatric conditions.
  • Personal or family history of congenital long QT syndrome or sudden death.
  • Concomitant use of drugs that are metabolised by and/or are inhibitors of CYP2D
  • Concomitant use of drugs that are substrates for the organic cation transporter
  • History of significant claustrophobia.
  • Fulfils any of the MRI contraindications on the standard site radiography screening questionnaire (e.g. history of surgery involving metal implants).

研究组 & 干预措施

HTL0009936 high dose

Experimental

high dose infusion

干预措施: HTL0009936 (Drug)

HTL0009936 low dose

Experimental

low dose infusion

干预措施: HTL0009936 (Drug)

HTL0009936 matching placebo

Placebo Comparator

matching infusion

干预措施: HTL0009936 matching placebo (Drug)

结局指标

主要结局

Blood oxygen level dependent (BOLD) signal in functional Magnetic Resonance Imaging (fMRI) of the brain areas associated with cognitive tasks

时间窗: Day 1

次要结局

  • BOLD signal in fMRI in other brain regions involved in the regulation of cognitive processes during cognitive tasks(Day 1)
  • cerebral blood flow, assessed using Arterial Spin Labelling (ASL)(Day 1)
  • adverse events(Day 1)
  • blood pressure(Day 1)
  • 12-lead electrocardiogram(Day 1)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验